Intestinal Acid Sphingomyelinase Protects From Severe Pathogen-Driven Colitis

Inflammatory diseases of the gastrointestinal tract are emerging as a global problem with increased evidence and prevalence in numerous countries. A dysregulated sphingolipid metabolism occurs in patients with ulcerative colitis and is discussed to contribute to its pathogenesis. In the present study, we determined the impact of acid sphingomyelinase (Asm), which catalyzes the hydrolysis of sphingomyelin to ceramide, on the course of Citrobacter (C.) rodentium-driven colitis. C. rodentium is an enteric pathogen and induces colonic inflammation very similar to the pathology in patients with ulcerative colitis. We found that mice with Asm deficiency or Asm inhibition were strongly susceptible to C. rodentium infection. These mice showed increased levels of C. rodentium in the feces and were prone to bacterial spreading to the systemic organs. In addition, mice lacking Asm activity showed an uncontrolled inflammatory Th1 and Th17 response, which was accompanied by a stronger colonic pathology compared to infected wild type mice. These findings identified Asm as an essential regulator of mucosal immunity to the enteric pathogen C. rodentium.

[1]  M. Artola,et al.  Glycosphingolipids and Infection. Potential New Therapeutic Avenues , 2019, Front. Cell Dev. Biol..

[2]  S. Schneider‐Schaulies,et al.  Sphingomyelin Breakdown in T Cells: Role of Membrane Compartmentalization in T Cell Signaling and Interference by a Pathogen , 2019, Front. Cell Dev. Biol..

[3]  P. Wan,et al.  Inhibition of ASM activity ameliorates DSS-induced colitis in mice. , 2019, Prostaglandins & other lipid mediators.

[4]  J. Schneider-Schaulies,et al.  CD4+ Foxp3+ regulatory T cell-mediated immunomodulation by anti-depressants inhibiting acid sphingomyelinase , 2018, Biological chemistry.

[5]  Jianglin Fan,et al.  Sphingolipid de novo biosynthesis is essential for intestine cell survival and barrier function , 2018, Cell Death & Disease.

[6]  G. Ramachandran,et al.  Virulence of invasive Salmonella Typhimurium ST313 in animal models of infection , 2017, PLoS Neglected Tropical Diseases.

[7]  A. Bai,et al.  Acid sphingomyelinase mediates human CD4+ T-cell signaling: potential roles in T-cell responses and diseases , 2017, Cell Death and Disease.

[8]  B. Brüne,et al.  Ceramide synthase 2 deficiency aggravates AOM-DSS-induced colitis in mice: role of colon barrier integrity , 2017, Cellular and Molecular Life Sciences.

[9]  B. L. Johnson,et al.  Amitriptyline Usage Exacerbates the Immune Suppression Following Burn Injury , 2016, Shock.

[10]  E. Gulbins,et al.  Inhibition of Acid Sphingomyelinase Allows for Selective Targeting of CD4+ Conventional versus Foxp3+ Regulatory T Cells , 2016, The Journal of Immunology.

[11]  Phillips-Farfán Bryan,et al.  Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease , 2016, Mediators of inflammation.

[12]  P. Münzer,et al.  Acid Sphingomyelinase (ASM) is a Negative Regulator of Regulatory T Cell (Treg) Development , 2016, Cellular Physiology and Biochemistry.

[13]  S. Vermeire,et al.  Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. , 2016, The New England journal of medicine.

[14]  M. Maceyka,et al.  Sphingosine‐1‐phosphate phosphatase 2 promotes disruption of mucosal integrity, and contributes to ulcerative colitis in mice and humans , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  P. Mahzouni,et al.  Anti-inflammatory Effect of Amitriptyline on Ulcerative Colitis in Normal and Reserpine-Induced Depressed Rats , 2016, Iranian journal of pharmaceutical research : IJPR.

[16]  S. Robson,et al.  Role of acid sphingomyelinase bioactivity in human CD4+ T-cell activation and immune responses , 2015, Cell Death and Disease.

[17]  R. Klopfleisch,et al.  IL10-Deficiency in CD4+ T Cells Exacerbates the IFNγ and IL17 Response During Bacteria Induced Colitis , 2015, Cellular Physiology and Biochemistry.

[18]  T. Pritts,et al.  Acid sphingomyelinase inhibition protects mice from lung edema and lethal Staphylococcus aureus sepsis , 2015, Journal of Molecular Medicine.

[19]  Wenda Gao,et al.  CD39 and CD161 Modulate Th17 Responses in Crohn's Disease , 2014, The Journal of Immunology.

[20]  E. Gulbins,et al.  Inhibition of acid sphingomyelinase by tricyclic antidepressants and analogons , 2014, Front. Physiol..

[21]  B. Finlay,et al.  Citrobacter rodentium: infection, inflammation and the microbiota , 2014, Nature Reviews Microbiology.

[22]  A. Gruber,et al.  Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer. , 2014, Cancer research.

[23]  Sarah Spiegel,et al.  Sphingolipid metabolites in inflammatory disease , 2014, Nature.

[24]  G. Eberl,et al.  Regulatory T cells promote a protective Th17-associated immune response to intestinal bacterial infection with C. rodentium , 2014, Mucosal Immunology.

[25]  Yong-yu Li,et al.  Inflammatory bowel disease: pathogenesis. , 2014, World journal of gastroenterology.

[26]  M. Nussenzweig,et al.  Intestinal monocytes and macrophages are required for T cell polarization in response to Citrobacter rodentium , 2013, The Journal of experimental medicine.

[27]  S. Modrow,et al.  Pathogenesis , 2013, Molecular Virology.

[28]  E. Barnes,et al.  Prevention of infection caused by immunosuppressive drugs in gastroenterology , 2013, Therapeutic advances in chronic disease.

[29]  F. Powrie,et al.  CD4+ T-cell subsets in intestinal inflammation , 2013, Immunological reviews.

[30]  Eugene Y. Kim,et al.  Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. , 2013, Cancer cell.

[31]  H. Rahimi,et al.  Antidepressants can treat inflammatory bowel disease through regulation of the nuclear factor-κB/nitric oxide pathway and inhibition of cytokine production: A hypothesis. , 2012, World journal of gastrointestinal pharmacology and therapeutics.

[32]  U. Ozcelik,et al.  Different features of lung involvement in Niemann-Pick disease and Gaucher disease. , 2012, Respiratory medicine.

[33]  Nicholas A Feasey,et al.  Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa , 2012, The Lancet.

[34]  D. Cho,et al.  C6-ceramide enhances Interleukin-12-mediated T helper type 1 cell responses through a cyclooxygenase-2-dependent pathway. , 2012, Immunobiology.

[35]  D. Ardid,et al.  Immunopathogenesis of inflammatory bowel disease. , 2010, Self/nonself.

[36]  Soma Ghosh,et al.  An Investigation on in vitro and in vivo Antimicrobial Properties of the Antidepressant: Amitriptyline Hydrochloride , 2010, Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology].

[37]  J. Kornhuber,et al.  Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A Novel Pharmacological Group of Drugs with Broad Clinical Applications , 2010, Cellular Physiology and Biochemistry.

[38]  F. Shanahan,et al.  Involvement of T helper type 17 and regulatory T cell activity in Citrobacter rodentium invasion and inflammatory damage , 2009, Clinical and experimental immunology.

[39]  C. Sasakawa,et al.  Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. , 2009, Immunity.

[40]  Y. Hannun,et al.  A role for sphingosine kinase 1 in dextran sulfate sodium‐induced colitis , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  A. Galione,et al.  Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium , 2008, Nature Medicine.

[42]  Yusuf A. Hannun,et al.  Principles of bioactive lipid signalling: lessons from sphingolipids , 2008, Nature Reviews Molecular Cell Biology.

[43]  Caixia Ma,et al.  Modulation of Intestinal Goblet Cell Function during Infection by an Attaching and Effacing Bacterial Pathogen , 2007, Infection and Immunity.

[44]  G. Rogler,et al.  Exogenous sphingomyelinase causes impaired intestinal epithelial barrier function. , 2007, World journal of gastroenterology.

[45]  R. Eyanagi,et al.  Acid sphingomyelinase inhibition suppresses lipopolysaccharide‐mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium‐induced colitis in mice , 2007, Immunology.

[46]  Jesse T. Myers,et al.  Constitutive Acid Sphingomyelinase Enhances Early and Late Macrophage Killing of Salmonella enterica Serovar Typhimurium , 2007, Infection and Immunity.

[47]  W. Sandborn,et al.  Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.

[48]  M. Mathieu,et al.  Anti-inflammatory properties of desipramine and fluoxetine , 2007, Respiratory research.

[49]  J. Panés,et al.  Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. , 2006, Gastroenterology.

[50]  R. D. Hatton,et al.  Transforming growth factor-β induces development of the TH17 lineage , 2006, Nature.

[51]  L. Bry,et al.  CD4+-T-Cell Effector Functions and Costimulatory Requirements Essential for Surviving Mucosal Infection with Citrobacter rodentium , 2006, Infection and Immunity.

[52]  G. Dougan,et al.  Citrobacter rodentium of mice and man , 2005, Cellular microbiology.

[53]  B. McCollister,et al.  Repression of SPI2 transcription by nitric oxide-producing, IFNγ-activated macrophages promotes maturation of Salmonella phagosomes , 2005, The Journal of experimental medicine.

[54]  L. Bry,et al.  Critical Role of T Cell-Dependent Serum Antibody, but Not the Gut-Associated Lymphoid Tissue, for Surviving Acute Mucosal Infection with Citrobacter rodentium, an Attaching and Effacing Pathogen 1 , 2004, The Journal of Immunology.

[55]  P. Galtier,et al.  The mycotoxin fumonisin B1 alters the proliferation and the barrier function of porcine intestinal epithelial cells. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[56]  J. Löhler,et al.  Severe Impairment in Early Host Defense Against Listeria monocytogenes in Mice Deficient in Acid Sphingomyelinase 1 , 2003, The Journal of Immunology.

[57]  K. Magnusson,et al.  Disruption of Epithelial Barrier Integrity by Salmonella enterica Serovar Typhimurium Requires Geranylgeranylated Proteins , 2003, Infection and Immunity.

[58]  S. Clare,et al.  Impaired Resistance and Enhanced Pathology During Infection with a Noninvasive, Attaching-Effacing Enteric Bacterial Pathogen, Citrobacter rodentium, in Mice Lacking IL-12 or IFN-γ , 2002, The Journal of Immunology.

[59]  P. Gionchetti,et al.  Bacteria as the cause of ulcerative colitis , 2001, Gut.

[60]  G. Dougan,et al.  Citrobacter rodentium Infection in Mice Elicits a Mucosal Th1 Cytokine Response and Lesions Similar to Those in Murine Inflammatory Bowel Disease , 1999, Infection and Immunity.

[61]  C. Fiocchi.  Inflammatory bowel disease: etiology and pathogenesis. , 1998, Gastroenterology.

[62]  D. Perl,et al.  Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease , 1995, Nature Genetics.

[63]  I. Egbunike,et al.  Antidepressants in the Management of Chronic Pain Syndromes , 1990, Pharmacotherapy.

[64]  Eka Swadiansa.  The hypothesis , 1990 .

[65]  G. A. Mccain,et al.  Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. , 1986, Arthritis and rheumatism.

[66]  M. Farthing.  Treatment of irritable bowel syndrome , 1981, BMJ : British Medical Journal.

[67]  P. Mishra,et al.  Therapeutic trial of amitryptiline in the treatment of nocturnal enuresis--a controlled study. , 1980, Indian pediatrics.

[68]  D. Ziegler,et al.  Amitriptyline in the prophylaxis of migraine , 1976, Neurology.

[69]  C A TAGLIABUE,et al.  [Etiology and pathogenesis]. , 1954, La Semana medica.

[70]  M. Papich.  Amitriptyline Hydrochloride , 2021, Papich Handbook of Veterinary Drugs.

[71]  J. Kornhuber,et al.  Functional inhibitors of acid sphingomyelinase (FIASMAs). , 2013, Handbook of experimental pharmacology.

[72]  A. Nilsson,et al.  Metabolism of sphingolipids in the gut and its relation to inflammation and cancer development. , 2009, Progress in lipid research.

[73]  R. Sartor,et al.  Microbial factors in chronic intestinal inflammation , 1996 .